SEC Company Response from AGENUS INC (AGEN) (CIK 0001098972) (AGEN) — Jan 26, 2017
AGENUS INC (AGEN) (CIK 0001098972)
Date: Jan. 26, 2017 · CIK: 0001098972 · Accession: 0001193125-17-019193
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-215640
Letter
January 26, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Gabor
Suzanne Hayes
Re:
Agenus Inc.
Registration Statement on Form S-3, filed January 20, 2017
File No. 333-215640
Ladies and Gentlemen:
On behalf of Agenus Inc. (the “Company”), we submit via EDGAR this letter in response to the written comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “SEC”), dated January 25, 2017 (the “Comment Letter”), with regard to the Company’s above-referenced Registration Statement on Form S-3 (the “Registration Statement”). For the convenience of the Staff’s review, we have set forth the comments contained in the Comment Letter in italics followed by the response of the Company.
General
1. We note that you have a pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve any issues concerning the confidential treatment request.
Response:
The Company acknowledges the Staff’s comment that the Staff will not be in a position to declare the Company’s Registration Statement effective until any issues concerning the confidential treatment request are resolved.
Securities and Exchange Commission
Division of Corporation Finance
January 26, 2017
We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions or comments about this letter or need any further information, please call the undersigned at (617) 951- 7663.
Very
truly yours,
/s/ Zachary R. Blume
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 26, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Suzanne Hayes Re: Agenus Inc. Registration Statement on Form S-3, filed January 20, 2017 File No. 333-215640 Ladies and Gentlemen: On behalf of Agenus Inc. (the “Company”), we submit via EDGAR this letter in response to the written comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “SEC”), dated January 25, 2017 (the “Comment Letter”), with regard to the Company’s above-referenced Registration Statement on Form S-3 (the “Registration Statement”). For the convenience of the Staff’s review, we have set forth the comments contained in the Comment Letter in italics followed by the response of the Company. General 1. We note that you have a pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve any issues concerning the confidential treatment request. Response: The Company acknowledges the Staff’s comment that the Staff will not be in a position to declare the Company’s Registration Statement effective until any issues concerning the confidential treatment request are resolved. Securities and Exchange Commission Division of Corporation Finance January 26, 2017 We hope that the foregoing has been responsive to the Staff’s comments. If you have any questions or comments about this letter or need any further information, please call the undersigned at (617) 951- 7663. Very truly yours, /s/ Zachary R. Blume Zachary R. Blume cc: Evan Kearns (Agenus Inc.) 2